First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position.
Oxurion NV Business and Financial Update – FY 2020 apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Bicycle Therapeutics plc: Bicycle Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
Bicycle technology, today announced that management will participate in a fireside chat at the Oppenheimer 31
st Annual Healthcare Conference on March 16, 2021 at 8:40 a.m. ET. The conference will be held in a virtual meeting format.
A live webcast of the fireside chat will be accessible in the Investors Media section of Bicycle s website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the presentation date.
About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as
Oxurion NV: OXURION to Participate in Upcoming Investor Meetings finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.